Validity of Parametric MRI Using VIRADS

NARecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

December 31, 2026

Conditions
Bladder Cancer
Interventions
DIAGNOSTIC_TEST

Gadolinium

"All patients will be subjected to :~MRI examinations on a 1.5-T MRI system in the supine position by using a 16-channel pelvic phased-array coil. The MRI proto col includes the following sequences: unenhanced axial T1-WI, high-resolution three planes (axial, coronal, and sagittal) T2-WI, axial DWI with b values of 0, 800, and 1600 s/mm2, axial DCE T1-WI with three-dimensional (3D) high temporal resolution. In all sequences, the small field of view (FOV) was used with the scope of viewing the entire bladder, proximal urethra, distal ureteral orifices, and adjacent pelvic organs. Gadopentetate dimeglumine (Gadovist, 0.1 ml/kg body weight) is administered at a rate of 2 ml/s using a power injector."

Trial Locations (1)

Unknown

RECRUITING

Assuit university, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT05783271 - Validity of Parametric MRI Using VIRADS | Biotech Hunter | Biotech Hunter